Laura Tadvalkar - 26 Apr 2024 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: Director
Signature: /s/ Shane Ward, Attorney-in-Fact
Issuer symbol: CDTX
Transactions as of: 26 Apr 2024
Net transactions value: $0
Form type: 4
Filing time: 30 Apr 2024, 16:07:55 UTC
Previous filing: 30 Apr 2024
Next filing: 19 Jul 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDTX	Stock Option (right to buy)	Award	$0	+4,250		$0.000000	4,250	26 Apr 2024	Common Stock	4,250	$12.63	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/3rd of the total number of shares subject to the award shall vest on April 26, 2025 and the remaining 2/3rds of the shares will vest in equal monthly installments over a two year period such that the option is fully vested on April 26, 2027.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

1/3rd of the total number of shares subject to the award shall vest on April 26, 2025 and the remaining 2/3rds of the shares will vest in equal monthly installments over a two year period such that the option is fully vested on April 26, 2027.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.